^
    Evidence Level:
    Sensitive: B - Late Trials

    [Chr del(17p)-Chronic Lymphocytic Leukemia-venetoclax + rituximab]

    Source:
    J Clin Oncol
    Test:

    Vysis CLL FISH Probe Kit

    Title:
    Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
    Published date:
    09/28/2020
    Excerpt:
    Patients with CLL were randomly assigned to 2 years of venetoclax (VenR for the first six cycles) or six cycles of BR….Of 389 patients, 194 were assigned to VenR and 195 to BR....In the VenR arm, a significant impact of del(17p) on PFS (P < .01) was seen in patients with high-GC status but not patients with low-GC status or noncomplex GC.
    DOI:
    10.1200/JCO.20.00948
    Trial ID:
    MURANO
    Evidence Level:
    Sensitive: C3 – Early Trials

    [Chr del(17p)-Chronic Lymphocytic Leukemia-venetoclax]

    Source:
    Lancet Oncol
    Test:

    Vysis CLL FISH Probe Kit

    Title:
    Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
    Published date:
    06/01/2016
    Excerpt:
    ...this phase 2, single-arm, multicentre study, we recruited patients aged 18 years and older with del(17p) relapsed or refractory chronic lymphocytic leukaemia...At a median follow-up of 12·1 months (IQR 10·1-14·2), an overall response by independent review was achieved in 85 (79·4%; 95% CI 70·5-86·6) of 107 patients. Results of this trial show that venetoclax monotherapy is active and well tolerated in patients with relapsed or refractory del(17p) chronic lymphocytic leukaemia...
    DOI:
    10.1016/S1470-2045(16)30019-5
    Trial ID:
    NCT01889186